> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Modified Definity for Echocardiograms
- URL: https://www.fdaweb.com/fda-approves-modified-definity-for-echocardiograms/
- Published: 2020-11-19T12:00:00.000Z
- Updated: 2026-09-14T16:37:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148134

FDA has approved a Lantheus Holdings and Progenics Pharmaceuticals supplemental NDA for Definity Room Temperature (perflutren lipid microsphere) injectable suspension, an ultrasound enhancing agent intended for use to enhance suboptimal echocardiograms. Its modified formulation allows both storage and shipment at room temperature (Definity’s previously approved formulation requires refrigerated storage). The product is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.